CleveMed, a provider of home sleep apnea testing (HSAT) solutions, was issued another patent (9,533,114) that relates to its flagship product: SleepView. The patent is entitled “Integrated Diagnostic and Therapeutic System and Method Improving Treatment of Subject with Complex and Central Sleep Apnea.”
“This is our fourth issued patent on this technology covering at home titration and efficacy of CPAP therapy,” says Brian Kolkowski, PhD, JD, CleveMed executive vice president and patent attorney, in a release. “We have a number of other pending patents that will further expand coverage in this upcoming significant market.”
Hani Kayyali, CleveMed president, says, “We are very excited about this new patent. The need to conduct a more extensive evaluation of sleep apnea therapy, especially positive airway pressure (PAP), in the home is becoming very important because it can provide physicians with comprehensive patient data cost effectively. This is especially true for millions of patients whose response to treatment can be compromised by confounding diseases that often develop over time.”
CleveMed offers a wide range of sleep testing equipment, services, and cloud based technologies that allow sleep disorders to be monitored in the home, including Sapphire PSG, SleepScout, SleepView, SleepViewSM Web-portal, and SleepView Direct. CleveMed’s goal is to expand the reach of sleep medicine with technologies that speed diagnosis for providers, reduce healthcare costs for payers, and improve patients’ experiences in the home.